Amylin & Takeda Stop PhII Obesity Study

Amylin and Takeda have suspended a mid-stage clinical trial of a combination obesity treatment.

Amylin Pharmaceuticals Inc. and Takeda Pharmaceutical Co. Ltd. said Wednesday they have suspended a Phase II trial of their obesity drug, a combination of diabetes drug pramlintide and analogue hormone metreleptin. The study was halted for the companies to investigate a new antibody-related laboratory with metreleptin treatment in two patients who participated in a previously completed clinical study of obesity.

"The safety of patients in our clinical programs is of paramount concern to the companies. We have taken this precaution so that we can thorou

Related News

News CPHI Podcast Series: The power of proteins in antibody drug development

In the latest episode of the CPHI Podcast Series, Lucy Chard is joined by Thomas Cornell from Abzena to discuss protein engineering for drug design and development.

17 Sep 2024
News Amgen sues Samsung biologics unit over biosimilar for bone disease

Samsung Bioepis, the biologics unit of Samsung, has been issued a lawsuit brought forth by Amgen over proposed biosimilars of Amgen’s bone drugs Prolia and Xgeva.

14 Aug 2024
News CPHI Podcast Series: Why we need to consider women in clinical trials

The latest episode of the CPHI Podcast Series with Lucy Chard covers women's health, specifically women's representation in clinical trials, the associated bias, and the impacts on health for this population.

13 Aug 2024
News US FDA does not approve MDMA therapy for PTSD, requests more data

The MDMA-based therapeutic developed by Lykos Therapeutics, a California-based Public Benefit Corporation (PBC), has been reviewed and unapproved by the US FDA. The regulator has requested additional phase III trial data for further safety and efficacy...

12 Aug 2024
News Novartis and Viatris latest facing lawsuit over HeLa cell misuse

Global pharmaceutical companies Novartis and Viatris are the latest hit with a lawsuit claim pertaining to alleged misuse of the ‘HeLa’ cell line from the estate of woman whose cancerous tissue cells were taken without consent.

7 Aug 2024
News Sanofi invests billions into Frankfurt insulin production site

French pharmaceutical company Sanofi have announced an investment of EUR1.3 billion at their existing BioCampus site in Frankfurt am Main for the expansion of insulin production.

2 Aug 2024
News Novel oral Type 1 diabetes drug gains US FDA IND designation

A University of Alabama at Birmingham startup has gained FDA clearance for Investigational New Drug clinical trials for an oral Type 1 diabetes drug, a milestone for diabetes treatment.

1 Aug 2024
News A Day in the Life of a Vice President in R&D & Engineering

In the Day in the Life of Series, we've already had the chance to get to know a range of people in various roles in the pharma industry. In the latest interview we get a glimpse into the R&D side of things from Jennifer Sorrells, Vice Presiden...

23 Jul 2024

CPHI Online is the largest global marketplace in the pharma ingredients industry

Amylin & Takeda Stop PhII Obesity Study

Related News

Position your company at the heart of the global Pharma industry with a CPHI Online membership

Request for general information

Send a message to Please review your profile details to ensure it is up-to-date.

Send a message to
Please review your profile details to ensure it is up-to-date.